What Is Post-Cycle Therapy (PCT)? A Complete Recovery Guide
What Is Post-Cycle Therapy (PCT)? A Complete Recovery Guide
Post-cycle therapy is the protocol used after an anabolic steroid cycle to restore the body’s own testosterone production — a process suppressed, in varying degrees, by every anabolic steroid that has ever been used. The hypothalamic-pituitary-testicular axis, which normally governs testosterone output, shuts down in response to external androgens. When the cycle ends and those androgens clear, the axis must restart. Post-cycle therapy uses pharmacological tools — primarily selective estrogen receptor modulators — to accelerate that restart by stimulating LH and FSH secretion from the pituitary. This guide explains what the axis is, how suppression works, why recovery does not happen automatically or on a fixed schedule, and what post-cycle therapy is actually attempting to accomplish.
Post-Cycle Therapy — 3 Core Principles
Post-Cycle Therapy Restores a System, Not Just a Number
The goal of post-cycle therapy is not simply to raise a testosterone reading on a blood panel. It is to restore the full signaling cascade — hypothalamus releasing GnRH, pituitary responding with LH and FSH, testes responding with testosterone production — that the anabolic steroid cycle suppressed. A testosterone value returning to normal range during post-cycle therapy does not confirm that the underlying axis has recovered; it confirms that one output of the axis has normalized. LH and FSH recovery, tracked in bloodwork, is the signal that the axis itself is functioning again rather than testosterone being produced through a system that has only partially restarted.
Suppression Is Universal — Degree and Recovery Timeline Are Not
Every anabolic steroid suppresses the hypothalamic-pituitary-testicular axis. There are no exceptions: oral or injectable, mild or strong, short cycle or long, every exogenous androgen that binds androgen receptors triggers negative feedback at the hypothalamus and pituitary that reduces or eliminates LH and FSH secretion. What varies is the degree of suppression and the time required for recovery after the compound clears. A single short cycle with a mild compound may permit faster recovery than a long multi-compound cycle — but both require the axis to restart from a suppressed state, and neither restarts instantly when the last dose is taken.
Post-Cycle Therapy Is a Bridge, Not a Cure
Post-cycle therapy does not repair the axis — it stimulates it. Selective estrogen receptor modulators used in post-cycle therapy block estrogen’s negative feedback signal at the pituitary, allowing the pituitary to secrete more LH and FSH than it otherwise would during the recovery period. This stimulation gives the axis a signal to produce testosterone while its own regulation is re-establishing. Post-cycle therapy cannot force recovery if the underlying axis capacity has been permanently compromised by very long or repeated cycles. It can meaningfully accelerate a recovery that would otherwise occur more slowly — which is the entire basis for its use.
What This Guide Covers
Covered in This Guide
- The hypothalamic-pituitary-testicular axis — structure and normal function
- How anabolic steroids suppress LH, FSH, and endogenous testosterone production
- Why recovery does not begin automatically when a cycle ends
- What post-cycle therapy is designed to accomplish and its pharmacological mechanism
- How ester clearance determines when post-cycle therapy can begin
- Bloodwork markers for evaluating suppression depth and recovery progress
- Why recovery timelines vary and what factors influence them
Not Covered Here
- Specific PCT protocol structures or dosing guidance
- Tamoxifen, Clomiphene, or HCG in detail — covered in PCT Methods guides
- PCT for specific compounds or compound combinations
- Female hormonal recovery after anabolic steroid use
- TRT as an alternative to post-cycle therapy
- Sourcing, legality, or purchasing guidance for PCT compounds
This guide is part of the PCT section of MuscleScience.org. For foundational bloodwork context, see Blood Tests Before Steroids. For suppression mechanisms in individual compounds, see the Steroids hub. For hormonal recovery markers in the TRT context, see TRT Bloodwork.
The Hypothalamic-Pituitary-Testicular Axis — How It Normally Works
The hypothalamic-pituitary-testicular axis is the hormonal signaling system that governs endogenous testosterone production. Understanding post-cycle therapy requires understanding this axis — because suppression and recovery are both defined in terms of its function, not simply in terms of a testosterone blood level. Post-cycle therapy intervenes in this system at a specific point; knowing where that point is explains both what the intervention can accomplish and where its limits are.
The Three-Level Cascade
Hypothalamus — GnRH Pulse
The hypothalamus monitors circulating androgen and estrogen levels through androgen and estrogen receptors. When testosterone is low, the hypothalamus secretes gonadotropin-releasing hormone (GnRH) in pulses — the initiation signal for the entire cascade. When testosterone is high — whether endogenous or from exogenous androgens — the hypothalamus reduces GnRH pulse frequency and amplitude. This is the first point at which anabolic steroid use suppresses the axis.
Pituitary — LH and FSH Secretion
The anterior pituitary receives GnRH signals from the hypothalamus and responds by secreting luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH is the primary driver of testosterone production by Leydig cells in the testes. FSH governs spermatogenesis — sperm production. Without adequate GnRH signal, the pituitary does not secrete meaningful LH or FSH. Post-cycle therapy acts primarily at this level: SERMs block estrogen’s inhibitory feedback at the pituitary, allowing LH and FSH secretion to resume.
Testes — Testosterone and Sperm
Leydig cells in the testes receive LH signals and produce testosterone in response. Sertoli cells receive FSH signals and support sperm production. Without LH stimulation — absent during an anabolic steroid cycle — Leydig cells produce minimal testosterone and may undergo partial functional atrophy over longer cycles. Restoring the LH signal through post-cycle therapy restimulates Leydig cell activity. FSH-dependent sperm recovery typically lags behind testosterone recovery and may take longer to normalize after extended suppression.
The Feedback Loop That Maintains Balance Without Exogenous Androgens
Under normal conditions, the axis operates as a self-regulating negative feedback loop. When testosterone falls below the hypothalamus’s set point, GnRH pulses increase, LH and FSH rise, and the testes produce more testosterone. When testosterone rises above the set point, GnRH pulses decrease, LH and FSH fall, and testosterone production slows. This loop maintains testosterone within a physiological range through continuous dynamic adjustment. Anabolic steroids override it entirely: exogenous androgens satisfy the hypothalamus’s androgen receptors and trigger suppression regardless of what the testes are producing — or not producing. Post-cycle therapy’s job is to help this loop restart after the exogenous androgens have cleared.
How Anabolic Steroids Suppress the Axis and Why Post-Cycle Therapy Is Needed
Every anabolic steroid suppresses the hypothalamic-pituitary-testicular axis through the same fundamental mechanism: androgen receptor binding at the hypothalamus and pituitary, which signals the axis that androgen levels are sufficient and reduces or eliminates the GnRH-LH-FSH cascade. The result is that LH and FSH fall — sometimes to undetectable levels — and endogenous testosterone production ceases or is dramatically reduced. This is not a clinical side effect; it is the expected pharmacological consequence of providing exogenous androgens to a system built around androgen feedback. Post-cycle therapy exists precisely because this suppression does not reverse automatically when the cycle ends — and the factors below determine how deep suppression goes and how long recovery takes.
Four Factors That Determine Suppression Depth and Recovery Duration
Compound Androgenic Potency
Compounds with higher androgen receptor binding affinity produce more complete suppression at lower doses. Trenbolone produces rapid, near-total suppression at doses well below what testosterone requires to achieve the same suppressive effect. Milder compounds at low doses may produce partial suppression. Regardless of degree, all anabolic steroids suppress the axis at any meaningful performance dose — and the more potent the suppression signal during the cycle, the longer the axis may take to re-establish normal sensitivity after the compound clears.
Cycle Duration
Longer cycles produce deeper and more sustained suppression. Leydig cells deprived of LH stimulation over months rather than weeks may undergo functional desensitization — requiring more time to respond to restored LH signals during post-cycle therapy. Short cycles of eight weeks or less typically permit faster axis recovery than cycles of sixteen weeks or more, all else equal. This is one of the structural arguments for shorter cycle lengths when recovery speed is a priority.
Number of Compounds
Multi-compound cycles produce more complete suppression than single-compound cycles because each compound contributes its own androgen receptor stimulation at the hypothalamus and pituitary. Cycles that include 19-nor compounds such as nandrolone or trenbolone add a progestogenic suppression pathway on top of androgenic suppression — further deepening the overall suppression picture and extending the recovery timeline that post-cycle therapy must work against.
Individual Axis Sensitivity
Individual variation in HPTA sensitivity, Leydig cell reserve, and baseline hormonal function produces different recovery timelines from identical cycles. Age is a significant variable: older users typically have lower Leydig cell reserve and slower axis response to post-cycle therapy stimulation. Prior cycle history also matters — repeated cycles with insufficient recovery between them can progressively reduce the axis’s capacity to recover fully, making each subsequent recovery slower than the one before.
Why the Axis Does Not Restart Automatically When the Cycle Ends
Stopping an anabolic steroid cycle does not immediately restore the axis. The compound must first clear from the system — a process governed by ester half-life, ranging from days for short oral steroids and acetate esters to four to six weeks for nandrolone decanoate. Until clearance is complete, androgen receptor stimulation at the hypothalamus continues and the suppression signal persists. Once the compound has cleared, the axis begins receiving reduced androgen input — but the hypothalamus and pituitary do not respond instantly. The axis must re-establish its sensitivity to the changed hormonal environment, which takes additional time even under favorable conditions. During this window, testosterone may remain at sub-physiological levels while the restart is underway. Post-cycle therapy shortens this window by adding an upstream stimulation signal — restoring LH and FSH output — during the period when the axis is re-establishing its own feedback regulation. See Fertility and Suppression on Steroids for how suppression affects sperm production and fertility recovery specifically.
What Post-Cycle Therapy Is Designed to Accomplish
Post-cycle therapy is not a single compound or a fixed protocol — it is a strategy for accelerating the recovery of endogenous testosterone production after anabolic steroid suppression. The pharmacological foundation of post-cycle therapy is the selective estrogen receptor modulator (SERM): a compound that blocks estrogen receptors at the pituitary, reducing estrogen’s negative feedback contribution to LH and FSH suppression. With estrogen’s inhibitory signal at the pituitary reduced, the pituitary is more responsive to GnRH input from the hypothalamus — and LH and FSH secretion resumes more quickly than it would without pharmacological intervention during the recovery period.
What SERMs Do and Do Not Do
SERMs used in post-cycle therapy — most commonly tamoxifen and clomiphene — do not directly stimulate testosterone production. They act upstream: by reducing estrogen’s inhibitory signal at the pituitary, they allow the pituitary to secrete more LH. More LH reaches the Leydig cells, which then produce more testosterone in response. The testosterone rise that occurs during post-cycle therapy is a downstream consequence of upstream signal restoration — not a direct pharmacological effect on the testes. This distinction matters because it explains why post-cycle therapy works when the axis has the underlying capacity to respond, and why it may be insufficient when that capacity has been compromised by very prolonged suppression or repeated cycles without adequate recovery periods between them. Individual compound guides are available in the PCT Methods section.
The Role of HCG Alongside Post-Cycle Therapy
Human chorionic gonadotropin (HCG) mimics LH — it binds to LH receptors on Leydig cells and stimulates testosterone production directly, bypassing the pituitary. HCG is used before or alongside post-cycle therapy in situations where testicular atrophy from prolonged LH deprivation has reduced the testes’ sensitivity to LH signals. By stimulating the Leydig cells directly during the transition from a suppressed cycle to SERM-based recovery, HCG can help maintain Leydig cell function and preserve their responsiveness to the LH signal that post-cycle therapy will restore. HCG is not a post-cycle therapy in itself — it does not restore the signaling axis. It is a preparatory intervention that supports the testes’ capacity to respond when post-cycle therapy begins. Full coverage of HCG timing and use is available in the PCT Methods section.
When Post-Cycle Therapy Can Begin — Ester Clearance and Timing
Post-cycle therapy cannot begin while the suppressive compound is still active in the system. Starting a SERM while anabolic steroids are still present produces a pharmacological conflict: the SERM attempts to stimulate LH and FSH secretion from the pituitary while exogenous androgens simultaneously suppress it. The stimulation cannot overcome the suppression signal. Post-cycle therapy timing must therefore be based on ester clearance — the time required for the specific compound used to fall below a pharmacologically active concentration in the bloodstream.
Clearance Windows by Ester Type
2–4 Days After Last Dose
Oral anabolic steroids without 17aa modifications, and compounds with no ester, clear within days. Short oral cycles — Anavar, Winstrol tablets — clear in two to four days, allowing post-cycle therapy to begin relatively promptly after the last dose. Oral stanozolol has a half-life of approximately nine hours; meaningful clearance occurs within four to five days.
4–7 Days After Last Injection
Short-ester injectables such as trenbolone acetate and testosterone propionate clear within four to seven days of the last injection. This faster clearance is the primary harm-reduction argument for using short esters on a first exposure to a potent compound — if severe side effects develop, the compound clears quickly enough that post-cycle therapy can begin within the same week.
14–18 Days After Last Injection
Testosterone enanthate and cypionate have half-lives of approximately seven to ten days. Meaningful clearance — sufficient for post-cycle therapy to be effective — occurs approximately two weeks after the last injection. This is the most common ester class used in testosterone-based cycles, and the two-week wait is the most commonly referenced timing guideline for post-cycle therapy initiation after testosterone-only cycles.
4–6 Weeks After Last Injection
Nandrolone decanoate (Deca-Durabolin) and testosterone undecanoate have the longest clearance timelines of commonly used injectable esters. Meaningful clearance of nandrolone decanoate takes four to six weeks after the last injection. Post-cycle therapy initiated before this window provides no meaningful benefit and may give a false sense of having started recovery — the suppression signal is still active throughout.
Mixed cycles require the longest ester’s clearance timeline. When a cycle includes both a short and a long ester compound, post-cycle therapy timing is determined by the compound with the longest clearance requirement — not by the first compound to clear. A cycle combining testosterone propionate and nandrolone decanoate must wait for nandrolone decanoate clearance before post-cycle therapy can be effective, regardless of when the testosterone propionate clears.
6 Key Bloodwork Markers for Evaluating Post-Cycle Therapy Recovery
- 01 / LH (Luteinizing Hormone)
The Primary Signal That the Axis Has Restarted
LH is the direct output of pituitary function — the signal that the hypothalamic-pituitary-testicular axis is generating the cascade that drives testosterone production. During an anabolic steroid cycle, LH falls to undetectable levels. During post-cycle therapy, LH is the marker that most directly confirms the axis is responding: rising LH confirms the pituitary is secreting again, which in turn means the hypothalamus is generating GnRH pulses. A testosterone reading that normalizes without LH also normalizing is a flag that the axis has not fully recovered — testosterone may be rising through other mechanisms or at the lower range of normal while LH remains suppressed. Pre-cycle baseline LH is required to interpret post-cycle recovery values meaningfully.
- 02 / FSH (Follicle-Stimulating Hormone)
The Recovery Marker for Sperm Production
FSH governs spermatogenesis — the production of sperm within the Sertoli cells of the testes. Like LH, FSH falls to undetectable levels during anabolic steroid cycles and must recover during post-cycle therapy for sperm production to resume. FSH recovery typically lags behind LH recovery after a cycle, and may remain suppressed for longer after extended or heavy cycles. For users with fertility goals, FSH recovery is the primary marker that spermatogenesis has resumed — not subjective fertility symptoms or testosterone levels alone. See Fertility and Suppression on Steroids for detailed coverage of fertility recovery timelines.
- 03 / Total Testosterone
The Outcome Measure — Not the Only Measure
Total testosterone is the most commonly measured marker during post-cycle therapy and the one users focus on most heavily. It is an important outcome measure — confirming that testosterone production has returned to a functional level — but it is not the only marker that matters for axis recovery assessment. Total testosterone can return to the normal reference range while LH remains partially suppressed, while free testosterone remains functionally low due to elevated SHBG, or while FSH has not yet recovered sufficiently to restore spermatogenesis. Post-cycle therapy bloodwork that measures total testosterone in isolation does not provide a complete picture of recovery. See Total vs Free Testosterone.
- 04 / Free Testosterone
The Functionally Active Fraction — Often Lags Behind Total
Free testosterone — the fraction not bound to SHBG or albumin — is the pharmacologically active portion of total testosterone. During post-cycle therapy and the recovery period, SHBG often rises as estrogen fluctuates and the hormonal environment normalizes. Elevated SHBG binds more testosterone, reducing the free fraction even when total testosterone has returned to normal range. Users who rely on total testosterone alone during post-cycle therapy may overlook the fact that functional testosterone — the fraction available to bind androgen receptors — remains low. Symptoms of low testosterone during recovery, despite normal total testosterone on bloodwork, may reflect reduced free testosterone from SHBG elevation. See SHBG Explained.
- 05 / Estradiol
Fluctuates During Recovery — Requires Monitoring, Not Suppression
Estradiol levels fluctuate meaningfully during post-cycle therapy as the hormonal environment transitions from the suppressed state of the cycle toward normal physiological balance. This is expected and is part of the recovery process. A critical error during post-cycle therapy is aggressively suppressing estradiol with aromatase inhibitors in response to elevated estrogen readings early in recovery. Estrogen is required for normal LH pulsatility — estrogen acts on the hypothalamus and pituitary as part of the feedback system that governs GnRH and LH secretion. Suppressing estradiol too aggressively during post-cycle therapy disrupts the feedback signal that SERMs are attempting to leverage. Estradiol monitoring during recovery informs decisions; it does not automatically justify intervention. See Estradiol on TRT for reference ranges and interpretation context.
- 06 / Lipids and Liver Enzymes
Recovery Markers for Cardiovascular and Hepatic Health
Post-cycle therapy bloodwork should include lipids and liver enzymes — not only hormonal markers. HDL suppression from anabolic steroid use begins normalizing after cycle clearance, but recovery to pre-cycle values may take months, particularly after cycles with severe HDL suppression such as Winstrol or trenbolone. Liver enzymes elevated during a cycle — particularly GGT, ALT, and AST — should be monitored to confirm they are normalizing rather than remaining elevated. Persistent enzyme elevation after a cycle has cleared may indicate hepatic stress from a 17-alpha-alkylated compound that requires additional recovery time. See Lipid Panel: HDL, LDL, Triglycerides and Liver Markers: AST, ALT, GGT.
Post-Cycle Therapy — Recovery Bloodwork Panel
The table below covers the markers to include in a post-cycle therapy bloodwork panel, the timing for each check, and what the result indicates about recovery progress. A single panel at the start of post-cycle therapy and a follow-up at the end of the protocol provides the minimum data needed to assess whether recovery has occurred or is still in progress.
| Marker | When to Check | What It Indicates |
|---|---|---|
| LH | Before PCT, mid-PCT, end of PCT | Primary axis restart signal; rising LH confirms pituitary responding |
| FSH | Before PCT, end of PCT | Spermatogenesis recovery; typically lags LH recovery timeline |
| Total Testosterone | Before PCT, end of PCT, 4 weeks post-PCT | Primary outcome measure; confirm it holds after PCT ends |
| Free Testosterone | End of PCT, 4 weeks post-PCT | Functional active fraction; may lag total T if SHBG elevated |
| SHBG | End of PCT, 4 weeks post-PCT | Rises during recovery; context for interpreting free testosterone |
| Estradiol | Before PCT, mid-PCT if symptomatic | Fluctuates during recovery; monitor but do not suppress aggressively |
| HDL / LDL | End of PCT, 8–12 weeks post-PCT | Lipid recovery from cycle suppression; may take months to normalize |
| GGT / ALT / AST | End of PCT | Confirm hepatic recovery; persistent elevation warrants extended monitoring |
Post-PCT follow-up bloodwork matters as much as end-of-PCT bloodwork. Recovery that holds four to six weeks after completing post-cycle therapy — with LH, FSH, and testosterone all in normal range without pharmacological support — is the confirmation that the axis has genuinely recovered. Values that normalize during post-cycle therapy but drop again after SERMs are discontinued indicate that the axis has not yet recovered independently and may require an extended protocol or medical evaluation. See Blood Tests Before Steroids for baseline testing protocol.
5 Critical Mistakes in Post-Cycle Therapy
- Mistake
Starting Post-Cycle Therapy Before the Compound Has Cleared
Beginning post-cycle therapy while a suppressive compound is still pharmacologically active is the most fundamental timing error in recovery planning. SERMs stimulate LH and FSH secretion by reducing estrogen’s inhibitory feedback at the pituitary — but this stimulation cannot overcome an active androgen suppression signal. Starting post-cycle therapy one week after the last nandrolone decanoate injection, for example, means initiating a recovery protocol while four to five weeks of active compound remain in the system. The post-cycle therapy window is wasted on a period when recovery cannot meaningfully occur, and the protocol ends before genuine recovery has had time to begin. Clearance timing must be established for the specific compounds used — not applied from a different compound’s clearance window.
- Mistake
Judging Recovery by Testosterone Alone Without Checking LH and FSH
A testosterone reading within the normal reference range at the end of post-cycle therapy is frequently interpreted as confirmation that recovery is complete. This interpretation is incorrect unless LH and FSH have also recovered. Testosterone may normalize while LH remains partially suppressed — particularly after shorter post-cycle therapy protocols following long or heavy cycles. When LH remains suppressed and testosterone appears normal, the axis has not recovered: testosterone is being produced at a level that happens to fall within the reference range from a partially restarted system. Discontinuing post-cycle therapy on the basis of testosterone alone, without confirming LH and FSH recovery, risks a secondary drop in testosterone after SERMs are stopped — which is the confirmation that the axis was not actually independent.
- Mistake
Using Aromatase Inhibitors Aggressively to Suppress Estrogen During Recovery
Estradiol elevation during post-cycle therapy — a common occurrence as the hormonal environment transitions — is frequently treated with aromatase inhibitor dose increases. This approach misunderstands estrogen’s role in the axis recovery process. Estrogen acts on the hypothalamus and pituitary as part of the feedback system that governs GnRH and LH pulsatility. Adequate estrogen is required for normal LH secretion during recovery. Aggressively suppressing estradiol with aromatase inhibitors during post-cycle therapy removes a signal that the axis needs to function correctly, potentially slowing or impairing the LH recovery that post-cycle therapy is designed to produce. SERMs block estrogen’s inhibitory feedback at the pituitary — but they do not eliminate estrogen’s positive contributions to the signaling environment. Aromatase inhibitor use during post-cycle therapy should be conservative and symptom-driven, not reflexive.
- Mistake
Stopping Post-Cycle Therapy as Soon as Testosterone Feels Normal
Subjective symptom improvement — improved energy, libido recovery, mood normalization — during post-cycle therapy frequently occurs before bloodwork confirms that the axis has recovered independently. SERMs provide pharmacological stimulation of LH and FSH while they are being taken; symptoms improve because LH and testosterone are rising under that stimulation, not necessarily because the axis has recovered the capacity to sustain those levels without it. Stopping post-cycle therapy based on subjective improvement rather than bloodwork confirmation results in a predictable pattern: testosterone drops after SERMs are discontinued because the axis was not yet capable of sustaining production independently. Post-cycle therapy duration should be determined by bloodwork, not by how recovery feels mid-protocol.
- Mistake
Running No Bloodwork and Managing Recovery by Symptoms Alone
Post-cycle therapy managed entirely by subjective symptoms — without pre-cycle baseline, without post-cycle bloodwork to confirm clearance, without mid-protocol or end-of-protocol panels — cannot distinguish between genuine axis recovery and pharmacologically supported testosterone production that will drop when the SERM is stopped. Symptoms of low testosterone during recovery — fatigue, libido suppression, mood changes, poor sleep — overlap with symptoms of many other conditions and cannot reliably distinguish between partial recovery and full suppression. LH, FSH, and testosterone values provide the objective data that symptom assessment cannot. Managing post-cycle therapy without bloodwork is equivalent to navigating a cycle without pre-cycle panels — removing the only mechanism by which actual hormonal status can be assessed and managed rather than assumed.
Authoritative Sources
- NCBI StatPearls — Anabolic Steroids: Pharmacology, HPTA Suppression and Health Effects
- PubMed — Physical, Psychological and Biochemical Recovery from Anabolic Steroid-Induced Hypogonadism: A Scoping Review (2023)
- PubMed — Recovery of the Hypothalamic-Pituitary-Gonadal Axis in Men After Using Androgenic Anabolic Steroids
- PubMed — Are SERMs Safe and Effective for the Treatment of Hypogonadism in Men? (2022)
- PubMed — Understanding and Managing Suppression of Spermatogenesis Caused by Testosterone and Anabolic-Androgenic Steroids (2022)
- PubMed — Survey of Endocrinologists Managing Recovery from Anabolic Androgenic Steroid-Induced Hypogonadism (2023)
Post-Cycle Therapy — What It Is and What It Cannot Do
Post-cycle therapy is the pharmacological strategy for accelerating the recovery of endogenous testosterone production after anabolic steroid suppression. It works by using selective estrogen receptor modulators to reduce estrogen’s inhibitory feedback at the pituitary, allowing LH and FSH secretion to resume more quickly than it would without intervention. Post-cycle therapy timing is determined by compound clearance — it cannot begin while suppressive androgens remain active. Its effectiveness is determined by the depth of suppression, cycle duration, number of compounds used, and individual axis capacity to respond to LH stimulation.
Post-cycle therapy is not a guarantee of recovery. It is a bridge — a pharmacological support during the window between cycle clearance and independent axis function. Recovery that holds after post-cycle therapy ends, confirmed by bloodwork showing LH, FSH, and testosterone all within range without pharmacological support, is the only reliable confirmation that the axis has genuinely recovered. Bloodwork is not optional in this context: it is the only mechanism by which recovery can be confirmed rather than assumed. The five bloodwork markers that matter most — LH, FSH, total testosterone, free testosterone, and estradiol — each provide a different piece of the axis recovery picture that no other measurement can replace.
This article is published for educational and harm-reduction purposes only. Post-cycle therapy compounds — including tamoxifen, clomiphene, and HCG — are prescription medications in most jurisdictions. Nothing in this guide constitutes medical advice, a recommendation to use any compound, or guidance on sourcing or legal compliance. Readers assume full responsibility for any decisions made on the basis of information presented here.
All content on MuscleScience.org is produced by contributors working under pseudonyms for editorial independence and personal privacy. Author photographs are stylized portraits, not real images of the writers. See our About page for full editorial and anonymity disclosure.
We do not sell. We do not supply. We educate.
